Tuberculosis Research and Treatment / 2017 / Article / Tab 2

Research Article

Factors Associated with Mortality among Patients on TB Treatment in the Southern Region of Zimbabwe, 2013

Table 2

Clinical characteristics of TB patients in southern Zimbabwe, 2013.

CharacteristicsPercentage (95% CI)

TB category
 New1,6531,96984.0 (82.3–85.5)
 Retreatment3141,96915.9 (14.4–17.6)
 MDR-TB21,9690.1 (0.0–0.4)
 Missing data21,9710.1
Type of new TB
 Smear-positive PTB6031,65136.5 (34.2–38.9)
 Smear-negative PTB7201,65143.6 (41.2–46.0)
 EPTB2271,65113.7 (12.2–15.5)
 Smear-not-performed PTB1011,6516.1 (5.1–7.4)
 Missing21,6530.12
Type of retreatment TB
 Treatment after default293089.4 (6.6–13.2)
 Retreatment others19130862.0 (56.4–67.3)
 Relapse7830825.3 (20.8–30.5)
 Treatment after failure103083.2 (1.7–5.9)
 Missing data63141.9
HIV status
 HIV-negative4191,97121.3 (19.5–23.1)
 HIV-positive1,5381,97178.0 (76.1–79.8)
 Unknown141,9710.7 (0.4–1.2)
WHO clinical staging at ART
 I306384.7 (3.3–6.7)
 II7563811.8 (9.5–14.5)
 III49463877.4 (74.0–80.5)
 IV396386.1 (4.5–8.3)
 Missing data9001,53858.5
CD4 count (cells/mL) at ART
 ≤509636426.4 (22.1–31.2)
 51–20013736437.6 (32.8–42.8)
 201–3507436420.3 (16.5–24.8)
 351–500283647.7 (5.4–10.9)
 >500293648.0 (5.6–11.2)
 Missing data1,1741,53876.3
Median (IQR)132.5 (46; 282)
ART use
 No1391,5389.0 (7.7–10.6)
 Yes1,3991,53891.0 (89.4–92.3)
ART initiation in relation to start of TB
 >3 months before TB treatment4121,39929.4 (27.1–31.9)
 0–3 months before TB treatment1721,39912.3 (10.7–14.1)
 <2 weeks after TB treatment5431,39938.8 (36.3–41.4)
 2–8 weeks after TB treatment151,3991.1 (0.6–1.8)
 Not recorded2571,39918.4 (16.4–20.5)

CI = confidence interval; TB = tuberculosis; MDR-TB = multidrug resistant TB; PTB = pulmonary TB; EPTB = extrapulmonary PTB; HIV = human immunodeficiency virus; WHO = World Health Organisation; IQR = interquartile range; ART = antiretroviral therapy.
variables refer only to those who were diagnosed as HIV-positive.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.